Online citations, reference lists, and bibliographies.
← Back to Search

Malignant Pleural Effusion: Tumor-host Interactions Unleashed.

G. Stathopoulos, I. Kalomenidis
Published 2012 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Malignant pleural effusion (MPE) poses a significant clinical problem. Current nonetiologic management is suboptimal in terms of efficacy and safety. In light of recent research progress, we propose herein a new view of MPE development, which may rapidly translate into meaningful changes in therapeutics. In addition to tumor-induced impairment of pleural fluid drainage, pertinent findings point toward another pathway to MPE formation: a vicious loop of interactions between pleural-based tumor cells and the host vasculature and immune system that results in increased net fluid production via enhanced plasma extravasation into the pleural space. The ability of tumor cells to trigger this cascade likely rests on a specific and distinct transcriptional repertoire, which results in important vasoactive events in the pleural space. Although the characterization of tumor-derived factors responsible for MPE development is in the making, an additional, indirect path to MPE was recently demonstrated: tumor cells recruit and co-opt host cells and mediators, which, in turn, amplify tumor cell-primed fluid leakage and impact tumor cell functions. Importantly, recent evidence suggests that the biologic events that culminate in clinical MPE are likely amenable to therapeutic inhibition and even prevention. In this perspective, the scientific basis for an update of current concepts of MPE formation is highlighted. Key questions for future research are posed. Finally, a vision for novel, effective, safe, and convenient treatment modalities that can be offered to outpatients with MPE is set forth.
This paper references
10.1016/S0169-5002(02)00004-1
Intrabronchial orthotopic propagation of human lung adenocarcinoma--characterizations of tumorigenicity, invasion and metastasis.
K. Mase (2002)
10.1158/1535-7163.MCT-07-0118
Ovarian cancer cell–derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis
T. Hagemann (2007)
10.1136/thx.21.5.437
Metastatic carcinoma of the pleura.
P. C. Meyer (1966)
10.1164/rccm.200809-1522ST
An official research policy statement of the American Thoracic Society/European Respiratory Society: standards for quantitative assessment of lung structure.
C. Hsia (2010)
10.1038/onc.2010.107
Ovarian cancer ascites protects from TRAIL-induced cell death through αvβ5 integrin-mediated focal adhesion kinase and Akt activation
D. Lane (2010)
10.1371/journal.pone.0005884
The Malignant Pleural Effusion as a Model to Investigate Intratumoral Heterogeneity in Lung Cancer
S. Basak (2009)
10.1016/j.lungcan.2008.06.020
Osteopontin is involved in the formation of malignant pleural effusion in lung cancer.
R. Cui (2009)
10.1186/1476-4598-9-56
Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study
I. Psallidas (2009)
10.1038/ncponc1039
Advances in the systemic therapy of malignant pleural mesothelioma
D. Fennell (2008)
10.1093/ANNONC/MDL143
Bevacizumab is active in malignant effusion.
O. Pichelmayer (2006)
10.1097/JTO.0b013e318208c7c1
Thoracoscopic Assessment of Pleural Tumor Burden in Patients with Malignant Pleural Effusion: Prognostic and Therapeutic Implications
L. Sakr (2011)
10.1152/PHYSREV.1972.52.1.57
Mechanics of the pleural space.
E. Agostoni (1972)
10.1007/s002620050604
Synergistic effect of interleukin-15 and interleukin-12 on antitumor activity in a murine malignant pleurisy model
K. Kimura (2000)
10.1038/mt.2009.309
A Phase I Trial of Repeated Intrapleural Adenoviral-mediated Interferon-β Gene Transfer for Mesothelioma and Metastatic Pleural Effusions.
D. Sterman (2010)
10.1073/pnas.0604544103
Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters
B. Kroczynska (2006)
10.1152/JAPPLPHYSIOL.00494.2002
Albumin transcytosis from the pleural space.
E. Agostoni (2002)
10.1002/(SICI)1097-0215(19971210)73:6<844::AID-IJC14>3.0.CO;2-4
Genetic immunotherapy by intrapleural, intraperitoneal and subcutaneous injection of IL‐2 gene‐modified Lewis lung carcinoma cells
Y. Heike (1997)
10.1016/0169-5002(93)90360-a
A new patient-like metastatic model of human small-cell lung cancer constructed orthotopically with intact tissue via thoracotomy in nude mice.
X. Wang (1992)
10.1152/JAPPL.1991.70.1.123
No evidence for mesothelial cell contact across the costal pleural space of sheep.
K. Albertine (1991)
10.1067/MLC.2002.123267
Angiostatin II is the predominant glycoform in pleural effusates of rabbit VX-2 lung tumors.
M. C. Hatton (2002)
Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice.
L. Kraus-Berthier (2000)
10.1593/NEO.81480
The angiopoietin/Tie2 axis mediates malignant pleural effusion formation.
C. Moschos (2009)
10.1007/s12032-011-9960-6
Potential role of AQP1 and VEGF in the development of malignant pleural effusion in mice
J. Zhang (2011)
10.1152/PHYSREV.00026.2003
Pleural mechanics and fluid exchange.
S. Lai-Fook (2004)
10.1093/jnci/djn325
A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion.
G. Stathopoulos (2008)
10.1002/AR.1092120205
Blood supply of the caudal mediastinal lymph node in sheep
K. Albertine (1985)
10.1183/09031936.97.10081907
Pleural diseases related to metastatic malignancies.
S. Sahn (1997)
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
10.1002/ijc.22840
Malignant ascites protect against TRAIL‐induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells
D. Lane (2007)
10.1016/J.LAB.2005.08.014
Relationships among tumor burden, tumor size, and the changing concentrations of fibrin degradation products and fibrinolytic factors in the pleural effusions of rabbits with VX2 lung tumors.
M. C. Hatton (2006)
10.1111/j.1440-1843.2004.00566.x
Management of malignant pleural effusions
Y. Lee (2004)
10.1002/(SICI)1098-2744(199701)18:1<54::AID-MC7>3.0.CO;2-R
Characterization of the rat neurofibromatosis 2 gene and its involvement in asbestos‐induced mesothelioma
E. Kleymenova (1997)
10.1183/09031936.00165607
Pleural drainage and pleurodesis: implementation of guidelines in four hospitals
J. Burgers (2008)
10.1200/JCO.2005.04.2838
Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients.
J. P. Monk (2006)
10.1164/rccm.201001-0001OC
Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion.
G. Stathopoulos (2010)
10.1016/J.ATHORACSUR.2003.11.065
Images in cardiothoracic surgery. Active malignant pleural effusion captured through the thoracoscope.
A. Maker (2005)
10.1164/AJRCCM.165.1.2104006
Transforming Growth Factor β Induces Vascular Endothelial Growth Factor Elaboration from Pleural Mesothelial Cells in Vivo and in Vitro
Y. C. Lee (2002)
10.1164/rccm.200710-1513OC
Zoledronic acid is effective against experimental malignant pleural effusion.
G. Stathopoulos (2008)
10.1016/j.lungcan.2008.12.007
Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: correlations with patient survival and pleural effusion control.
I-Lin Hsu (2009)
10.1016/j.cllc.2011.02.006
EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.
Hye-Suk Han (2011)
10.1371/journal.pone.0006539
Epidermal Growth Factor Receptor Inhibition Modulates the Microenvironment by Vascular Normalization to Improve Chemotherapy and Radiotherapy Efficacy
G. Cerniglia (2009)
10.1136/thx.2010.136994
Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010
M. Roberts (2010)
10.1158/0008-5472.CAN-07-1064
Tumor Necrosis Factor-α Promotes Malignant Pleural Effusion
G. Stathopoulos (2007)
10.1165/RCMB.2005-0130OC
Nuclear Factor-κB Affects Tumor Progression in a Mouse Model of Malignant Pleural Effusion
G. Stathopoulos (2006)
10.1164/AJRCCM.162.3.9910050
Volume and cellular content of normal pleural fluid in humans examined by pleural lavage.
M. Noppen (2000)
10.1152/AJPLUNG.00012.2002
Oxidative stress and inflammation contribute to lung toxicity after a common breast cancer chemotherapy regimen.
A. Abushamaa (2002)
Metastatic human pleural ovarian cancer model constructed by orthotopic implantation of fresh histologically-intact patient carcinoma in nude mice.
P. Astoul (1993)
10.1164/rccm.200807-1125OC
Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment.
B. Grigoriu (2009)
10.1183/09031936.00167407
Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma
S. Wu (2008)
10.1016/J.LUNGCAN.2004.02.021
Enhancement of pleural dissemination and lymph node metastasis of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs).
H. Ishii (2004)
10.1242/dmm.000976
Mouse xenograft models vs GEM models for human cancer therapeutics
A. Richmond (2008)
10.1016/S0003-4975(00)01090-0
An improved orthotopic xenotransplant procedure for human lung cancer in SCID bg mice.
A. Boehle (2000)
10.1016/J.LAB.2004.01.006
Fibrinogen catabolism within the procoagulant VX-2 tumor of rabbit lung in vivo: Effluxing fibrin(ogen) fragments contain antiangiogenic activity.
M. C. Hatton (2004)
10.1152/JAPPL.1988.64.1.384
Removal of pleural liquid and protein by lymphatics in awake sheep.
V. Broaddus (1988)
10.1097/00063198-199707000-00011
Diseases of the pleura.
R. Light (1995)
10.1183/09031936.97.10010219
Physiology and pathophysiology of pleural fluid turnover.
Giuseppe Miserocchi (1997)
10.1007/s00432-009-0555-y
Therapeutic effects of recombinant human endostatin adenovirus in a mouse model of malignant pleural effusion
F. Fang (2009)
10.1111/j.1440-1843.2009.01536.x
Osteopontin is upregulated in malignant and inflammatory pleural effusions
C. Moschos (2009)
10.1111/j.1476-5381.1993.tb13553.x
Characterization of the increase in vascular permeability induced by vascular permeability factor in vivo
P. Collins (1993)
10.1152/AJPCELL.2000.279.6.C1744
Role of aquaporin water channels in pleural fluid dynamics.
Y. Song (2000)
10.1183/09031936.00061606
Talc mediates angiostasis in malignant pleural effusions via endostatin induction
N. Najmunnisa (2007)
10.1183/09031936.02.00062102
Physiology and pathophysiology of pleural fluid turnover
L. Zocchi (2002)
10.1038/onc.2012.57
Secreted phosphoprotein-1 directly provokes vascular leakage to foster malignant pleural effusion
I. Psallidas (2013)
10.1016/j.cell.2011.02.013
Hallmarks of Cancer: The Next Generation
D. Hanahan (2011)
10.1007/978-1-61779-523-7_5
Chicken chorioallantoic membrane angiogenesis model.
D. Ribatti (2012)
10.1002/path.1697
Advances in imaging mouse tumour models in vivo
S. Lyons (2005)
10.3727/000000003771013053
Pleural mesothelial cell (PMC) defense mechanisms against malignancy.
N. Nasreen (2003)
10.1016/j.lungcan.2010.12.005
A sulindac analogue is effective against malignant pleural effusion in mice.
C. Moschos (2011)
10.1158/1541-7786.MCR-07-0309
Host Nuclear Factor-κB Activation Potentiates Lung Cancer Metastasis
G. Stathopoulos (2008)
10.1038/sj.bjc.6605814
Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma
J. D. Veltman (2010)
10.1002/AR.1092080310
The structure of the parietal pleura and its relationship to pleural liquid dynamics in sheep
K. Albertine (1984)
10.1136/THORAX.58.SUPPL_2.II29
BTS guidelines for the management of malignant pleural effusions.
G. Antunes (2003)
10.3892/IJO.18.3.499
Biological characteristics of carcinomatosa pleuritis in orthotopic model systems using immune-deficient rats.
Y. Ohta (2001)
10.1165/RCMB.2004-0355OC
A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance.
Ki-Up Kim (2005)
10.1183/09031936.00063109
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
10.1158/1078-0432.CCR-08-2641
CCL22 Recruits CD4-positive CD25-positive Regulatory T Cells into Malignant Pleural Effusion
Xue-jun Qin (2009)
10.1164/RCCM.200504-588OC
CD4+CD25+ regulatory T lymphocytes in malignant pleural effusion.
Yiqiang Chen (2005)
10.2174/1568009054064624
The chick embryo chorioallantoic membrane as a model system for the study of tumor angiogenesis, invasion and development of anti-angiogenic agents.
T. Ac (2005)
Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions.
B. Zebrowski (1999)
10.1183/09031936.97.10081701
Malignant pleural effusion: would the real cause please stand up?
R. Light (1997)
10.1016/j.ccr.2008.01.030
A conditional mouse model for malignant mesothelioma.
J. Jongsma (2008)
Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
S. Yano (2000)
10.1111/j.1440-1843.2010.01890.x
Translational advances in pleural malignancies
Georgios T. Stathopoulos (2011)
10.1016/0363-0188(91)90021-S
Pleural diseases: multimodality imaging and clinical management.
C. Henschke (1991)
10.1016/j.ccr.2009.06.017
Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN.
Z. Fridlender (2009)
Serosal membranes (pleura, pericardium, peritoneum). Normal structure, development and experimental pathology.
K. Michailova (2006)
10.1200/JCO.2006.08.2099
Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.
G. Simon (2007)
10.3727/000000006783981062
Restored expression of the MYO18B gene suppresses orthotopic growth and the production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice.
Nobutaka Edakuni (2006)
10.1002/0471143030.cb1902s12
Tail Vein Assay of Cancer Metastasis
M. Elkin (2001)
10.1158/0008-5472.CAN-08-2678
Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis.
Jill K. Slack-Davis (2009)
10.1007/s10585-010-9324-1
A sensitive polymerase chain reaction-based method for detection and quantification of metastasis in human xenograft mouse models
A. Malek (2010)
10.1164/ARRD.1975.111.1.12
The preformed stomas connecting the pleural cavity and the lymphatics in the parietal pleura.
N. Wang (1975)
10.1038/sj.onc.1209464
Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion
H-H Yeh (2006)
10.1159/000065723
High Level of Vascular Endothelial Growth Factor in Hemorrhagic Pleural Effusion of Cancer
O. Ishimoto (2002)
10.1016/S0002-9440(10)64828-6
Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells.
S. Yano (2000)
10.1183/09031936.01.00225601
Management of malignant pleural effusions.
V. Antony (2001)



This paper is referenced by
10.18632/oncotarget.18824
Thoracic radiation-induced pleural effusion and risk factors in patients with lung cancer.
Jing Zhao (2017)
10.1007/s13277-016-5441-z
Chloroquine inhibits tumor growth and angiogenesis in malignant pleural effusion
Q. Li (2016)
10.3892/ol.2020.11446
Multiplexed molecular profiling of lung cancer with malignant pleural effusion using next generation sequencing in Chinese patients
Xingya Ruan (2020)
10.3126/KUMJ.V8I4.6243
Unusual site of metastasis of bronchogenic carcinoma.
P. Pant (2010)
10.21037/jlpm.2018.08.06
Malignant pleural effusion: first steps towards therapy
E. García-Pachón (2018)
10.1080/17476348.2020.1793672
Multidisciplinary approaches to the management of malignant pleural effusions: a guide for the clinician
R. Banka (2020)
10.14744/ejmo.2018.0114
Histologic Grade with Thyroid Transcription Factor 1 and Sample Type Serve as Independent Factors for the Incidence of EGFR Mutations in Non-small Cell Lung Cancer
Hang Thi Thuy Nguyen (2019)
10.1080/23809000.2016.1142358
The role of interventional oncology in the palliative care of cancer patients
D. Li (2016)
10.5795/JJSCC.55.315
The significance of pleural fluid aspiration cytology in hematologic malignancies: —A single-institution study—
Shigemi Ito (2016)
10.1371/journal.pone.0071207
Beneficial Impact of CCL2 and CCL12 Neutralization on Experimental Malignant Pleural Effusion
A. Marazioti (2013)
10.1101/2020.05.31.20118307
Clinical identification of malignant pleural effusions in the emergency department
G. Stathopoulos (2020)
10.1126/sciadv.aay9789
Irradiated tumor cell–derived microparticles mediate tumor eradication via cell killing and immune reprogramming
C. Wan (2020)
10.1111/resp.12354
Staphylococcus aureus bio‐products: New biological roles for a pleurodesis agent
I. Psallidas (2014)
10.1016/J.JASC.2015.01.009
Clinical presentation and cytopathologic features of malignant pericardial cytology: a single institution analysis spanning a 29-year period.
H. Zhu (2015)
10.3892/etm.2014.1503
Pleural fluid prealbumin and C-reactive protein in the differential diagnosis of infectious and malignant pleural effusions
Qiaoying Ji (2014)
10.1016/S1877-1203(13)70383-5
Les pleurésies cancéreuses : traitement local
Sylvie Jaillard (2013)
10.1177/1753465815570307
Efficacy and safety profile of autologous blood versus tetracycline pleurodesis for malignant pleural effusion
W. Keeratichananont (2015)
10.4161/onci.29195
Monoclonal antibody targeting of mononuclear cell chemokines driving malignant pleural effusion
A. Marazioti (2014)
10.1183/2312508x.10032719
In vitro and in vivo laboratory models of pleural disease
Xuan Yao (2020)
10.7150/THNO.34070
Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer
L. Tong (2019)
10.18632/oncotarget.7912
Icmt inhibition exerts anti-angiogenic and anti-hyperpermeability activities impeding malignant pleural effusion
Sophia F Magkouta (2016)
10.1007/s12094-015-1464-y
Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases
D. Márquez-Medina (2015)
10.3892/mmr.2018.8922
The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non-small cell lung cancer
Y. Chen (2018)
10.3978/j.issn.2072-1439.2015.05.20
Switching off malignant pleural effusion formation-fantasy or future?
M. Spella (2015)
10.1007/s00262-020-02781-8
The M1/M2 spectrum and plasticity of malignant pleural effusion-macrophage in advanced lung cancer
M. Wu (2020)
10.5799/AHINJS.01.2012.02.0148
Malign plevral efüzyonlu olgularda randomize olarak VATS plörektomi ile küçük kalibrasyonlu kataterle talk plörodezis sonuçlarının karşılaştırılması
Fatih Meteroğlu (2012)
10.1126/scitranslmed.aat5690
Autologous tumor cell–derived microparticle-based targeted chemotherapy in lung cancer patients with malignant pleural effusion
M. Guo (2019)
10.1111/resp.12328
Interventional therapies for malignant pleural effusions: The present and the future
Rajesh Thomas (2014)
10.1080/2162402X.2015.1122861
Tumor evasion of humoral immunity mediated by proteolytic impairment of antibody triggered immune effector function
Ningyan Zhang (2016)
10.1016/s2213-2600(19)30373-x
Malignant pleural effusion management: keeping the flood gates shut.
S. Walker (2019)
10.1016/j.lungcan.2019.11.013
Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.
P. Stockhammer (2019)
10.1186/s12957-015-0729-9
Thoracic perfusion of matrine as an adjuvant treatment improves the control of the malignant pleural effusions
Rong Biaoxue (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar